These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 10220609

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD.
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract] [Full Text] [Related]

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM.
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract] [Full Text] [Related]

  • 3. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V, Vandross A.
    Arch Intern Med; 2012 Apr 23; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [Abstract] [Full Text] [Related]

  • 4. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
    Arrieta A, Page TF, Veledar E, Nasir K.
    PLoS One; 2017 Apr 23; 12(1):e0169761. PubMed ID: 28081164
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomics of lipid-lowering drugs.
    Smith DG.
    Curr Atheroscler Rep; 2003 Jan 23; 5(1):67-72. PubMed ID: 12562545
    [Abstract] [Full Text] [Related]

  • 6. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP.
    Am Heart J; 1999 May 23; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract] [Full Text] [Related]

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R.
    Am Heart J; 1999 May 23; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract] [Full Text] [Related]

  • 8. The economics of cardiovascular disease in the United States.
    Chen J, Rizzo JA.
    Crit Care Clin; 2012 Jan 23; 28(1):77-88, vi. PubMed ID: 22123100
    [Abstract] [Full Text] [Related]

  • 9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS.
    Am Heart J; 1999 May 23; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract] [Full Text] [Related]

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective.
    Boccuzzi SJ.
    Am Heart J; 1999 May 23; 137(5):S120-2. PubMed ID: 10220612
    [No Abstract] [Full Text] [Related]

  • 11. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside.
    Kazi DS, Virani SS.
    Prog Cardiovasc Dis; 2019 May 23; 62(5):406-413. PubMed ID: 31672610
    [Abstract] [Full Text] [Related]

  • 12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction.
    Lewandowski CA, Kahler J.
    Am Heart J; 1999 May 23; 137(5):S94-6. PubMed ID: 10220607
    [No Abstract] [Full Text] [Related]

  • 13. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA.
    Am J Cardiol; 1998 Sep 24; 82(6A):26M-31M. PubMed ID: 9766345
    [Abstract] [Full Text] [Related]

  • 14. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.
    Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, Pandor A.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct 24; 9(5):423-33. PubMed ID: 19817526
    [Abstract] [Full Text] [Related]

  • 15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ.
    Am Heart J; 1999 May 24; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract] [Full Text] [Related]

  • 16. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
    DeLong ER, Simons T.
    Am Heart J; 1999 May 24; 137(5):S47-50. PubMed ID: 10220596
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of a medical aid administrator database for costs and utilisation of benefits by patients claiming for lipid-lowering agents.
    Moodley I.
    Cardiovasc J S Afr; 2006 May 24; 17(3):140-5. PubMed ID: 16807632
    [Abstract] [Full Text] [Related]

  • 18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A, Schmier JK, Luce BR.
    Am Heart J; 1999 May 24; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract] [Full Text] [Related]

  • 19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS.
    Am Heart J; 1999 May 24; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract] [Full Text] [Related]

  • 20. Clinical trials. Lipid-lowering therapy and postoperative complications.
    DeSilvey DL.
    Am J Geriatr Cardiol; 2004 May 24; 13(5):278. PubMed ID: 15365293
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.